NASDAQ:PASG

Passage Bio Stock Insider Trading

Healthcare > Biotechnology

Buy PASG

*Your capital is at risk

$5.97

+0.0750 (+1.27%)

At Close: Jun 03, 2026

Passage Bio Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 36.45. In total, the insiders bought 7.11M and sold 3.47M PASG shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	36.45
● Buy	7.11M shares
● Sell	3.47M shares
54% Buy Activity Moderate Positive Correlation
Buy Signal Medium Confidence Mar 16, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 36.45. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 19, 2026 Buy	Director Stock Option (right to buy) A-Award	Countouriotis Athena Director	Director	10 539 Value: $53.5K
May 19, 2026 Buy	Director Stock Option (right to buy) A-Award	Gowen Maxine Director	Director	10 539 Value: $53.5K
May 19, 2026 Buy	Director Stock Option (right to buy) A-Award	Kapadia Sandip Director	Director	10 539 Value: $53.5K
May 19, 2026 Buy	Director Stock Option (right to buy) A-Award	Sondhi Dolan Director	Director	10 539 Value: $53.5K
May 19, 2026 Buy	Director Stock Option (right to buy) A-Award	Porter Derrell Director	Director	10 539 Value: $53.5K
May 19, 2026 Buy	Director Stock Option (right to buy) A-Award	Kassberg Thomas Richard Director	Director	10 539 Value: $53.5K
Mar 16, 2026 Buy	Employee Stock Option (right to buy) A-Award	Chou William President And CEO	CEO / President	58 000 Value: $443.1K
Mar 16, 2026 Buy	Employee Stock Option (right to buy) A-Award	Borthwick Kathleen CFO	C-Suite Officer	15 610 Value: $119.3K
Jan 08, 2026 Buy	Restricted Stock Unit M-Exempt	Borthwick Kathleen CFO	C-Suite Officer	5 000 Value: $91.7K
Jan 08, 2026 Buy	Common Stock M-Exempt	Borthwick Kathleen CFO	C-Suite Officer	5 000 Value: $91.7K
Jan 08, 2026 Buy	Common Stock M-Exempt	Chou William President And CEO	CEO / President	10 000 Value: $183.3K
Jan 08, 2026 Buy	Restricted Stock Unit M-Exempt	Chou William President And CEO	CEO / President	10 000 Value: $183.3K
Jan 08, 2026 Sell	Common Stock S-Sale	Chou William President And CEO	CEO / President	4 076 Value: $75.2K
Jan 08, 2026 Sell	Common Stock S-Sale	Borthwick Kathleen CFO	C-Suite Officer	2 062 Value: $38.0K
Sep 15, 2025 Buy	Common Stock P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	11 900 Value: $83.2K
Sep 15, 2025 Buy	Common Stock P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	11 900 Value: $83.2K
Sep 12, 2025 Buy	Common Stock P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	19 783 Value: $138.3K
Sep 12, 2025 Buy	Common Stock P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	19 783 Value: $138.3K
Sep 11, 2025 Buy	Common stock, $0.0001 par value per share (Common Stock) P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	325 Value: $2K
Sep 11, 2025 Buy	Common stock, $0.0001 par value per share (Common Stock) P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	325 Value: $2K
Jul 24, 2025 Buy	Common Stock P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	66 423 Value: $379.5K
Jul 24, 2025 Buy	Common Stock P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	66 423 Value: $379.5K
Jul 23, 2025 Buy	Common Stock P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	49 302 Value: $283.0K
Jul 23, 2025 Buy	Common Stock P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	49 302 Value: $283.0K
Jul 22, 2025 Buy	Common stock, $0.0001 par value per share ("Common Stock") P-Purchase	Lynx1 Capital Management Lp 10 Percent Owner	10% Owner	13 123 Value: $71.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PASSAGE BIO, INC.

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the...

Read Full Profile Here